AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Pharmaceutical Companies

684.072

-0.633-0.09%

Number of Gainers:9

Number of Losers:17

Number of Flat:17

PE:- -

High:690.137

Open:686.562

Low:679.584

Close:684.704

Volume:35.43M

Turnover:89.55M

Market Cap:98.35B

Float Cap:95.23B

Loading ...

Immutep Regains Compliance with NASDAQ Minimum Bid Price Requirement

THOMSON REUTERS

Immuron Says Phase 2 Travelan Trial Results Published in Scientific Reports

Travelan® Phase 2 Study Results Published

THOMSON REUTERS

Immutep Ltd - Regains Compliance with NASDAQ

THOMSON REUTERS

Orthocell to Present Initial Five-Patient Case Series for Use of Nerve Repair Product in Patients Undergoing Prostatectomy; Shares Up 4%

MT Newswires Live

ASX Growth Companies With Up To 30% Insider Ownership

Simply Wall St.

ASX Penny Stocks To Watch In October 2026

Simply Wall St.

Racura Oncology Clears RC220 Dose Escalation to 100 Mg/m2 in Phase 1 Harness-1 NSCLC Trial

Racura Oncology Cleared to Escalate Rc220 to 100 Mg/M2 in Phase 1 Harness-1 Trial in Egfr-Mutant Non-Small Cell Lung Cancer

THOMSON REUTERS

Racura Oncology Says Safety Review Committee Approved Planned Dose Escalation in Phase 1 Lung Cancer Combination Therapy Trial

MT Newswires Live

Acrux - FDA Confirms Two 24-Week Phase Iii Trials Required for Efficacy in Hsdd

THOMSON REUTERS

Acrux - FDA Confirms Acrux Eligible to Apply for 3-Year Exclusivity Period

THOMSON REUTERS

Acrux Ltd-FDA Clears Regulatory Pathway for Female Testosterone Mdts

THOMSON REUTERS

ASX Growth Stocks Insiders Are Betting On

Simply Wall St.

Top 3 Australian Founder Led Growth Stocks To Watch In October 2026

Simply Wall St.

Is Building Envelope Expansion Altering The Investment Case For Carlisle Companies (CSL)?

Simply Wall St.

Why PolyNovo Fell Even As Sales Rose

Simply Wall St.

Thailand's Forex Reserves Fall to $276.1 Billion in September

MT Newswires Live

Australia's CSL Rises After Jefferies Sees Plasma Yield Upside

Terumo, CSL Plasma Mutually Terminate Supply Agreement; Terumo Expects $610 Million Loss

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigermarketd.com/stock/BK7508/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK7508","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7508\",,,,,undefined,":{"symbol":"BK7508","market":"AU","secType":"PLATE","nameCN":"Pharmaceutical Companies","latestPrice":684.0717,"timestamp":1791867599870,"preClose":684.7042,"halted":0,"volume":35433199,"delay":0,"changeRate":-0.000924,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Closed","change":-0.632507,"latestTime":"10-13 16:00:00 AEDT","open":686.5619,"high":690.13727,"low":679.58386,"amount":89551098,"amplitude":0.015413,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1791932400000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1791846000000,1791867600000]],"turnoverRate":0.001409,"increases":9,"decrements":17,"flats":16,"marketCap":98347291455,"floatMarketCap":95233836805.5625},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7508\",,,,,undefined,":{"symbol":"BK7508","high":690.13727,"amplitude":0.015413,"preClose":684.7042,"low":679.58386,"latestPrice":684.0717,"volume":35433199,"delay":0,"open":686.5619,"prevYearClose":644.3692,"prevWeekClose":680.226,"prevMonthClose":689.549,"prevQuarterClose":689.549,"fiveDayClose":667.445,"twentyDayClose":659.123,"sixtyDayClose":486.546,"secType":"PLATE","market":"AU","turnoverRate":0.001409,"marketCap":98347291455,"floatMarketCap":95233836805.5625,"timestamp":1791867599870,"nameCN":"Pharmaceutical Companies"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK7508\",,,,undefined,":{"bkCode":"BK7508","up":9,"down":17,"flat":17},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK7508\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2675351874","title":"Immutep Regains Compliance with NASDAQ Minimum Bid Price Requirement","url":"https://stock-news.laohu8.com/highlight/detail?id=2675351874","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675351874?lang=en_us&edition=fundamental","pubTime":"2026-10-13 20:00","pubTimestamp":1791892805,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261013:nTUA48QTFY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMM.AU","BK7067","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675358596","title":"Immuron Says Phase 2 Travelan Trial Results Published in Scientific Reports","url":"https://stock-news.laohu8.com/highlight/detail?id=2675358596","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675358596?lang=en_us&edition=fundamental","pubTime":"2026-10-13 18:02","pubTimestamp":1791885733,"startTime":"0","endTime":"0","summary":"Immuron says Phase 2 Travelan trial results published in Scientific ReportsImmuron reported publication of Phase 2 results for once-daily oral Travelan inScientific Reports; data were previously prese","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261013:nNDLW89Lg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","LU2095319765.USD","SG9999014021.USD","SG9999014013.SGD","IE00B3QW5Z07.USD","LU2210149790.SGD","SG9999014039.USD","LU2210150020.SGD","BK4112","BK7508","LU0314104364.USD","IE00BQXX3C00.GBP","IE00BN0W2T93.GBP","BK4588","SG9999014005.SGD","IE00BQXX3D17.EUR","BK7067","NDAQ","IE00BN0W2W23.USD","IE00BKPKM429.USD","IE00BGHQF748.EUR","BK4585","IMC.AU","IE00BN0W2V16.EUR","IE00BQXX3F31.USD","BCDF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675358895","title":"Travelan® Phase 2 Study Results Published","url":"https://stock-news.laohu8.com/highlight/detail?id=2675358895","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675358895?lang=en_us&edition=fundamental","pubTime":"2026-10-13 18:00","pubTimestamp":1791885601,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261013:nTUA3WBBFL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMC.AU","BK7508","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675386074","title":"Immutep Ltd - Regains Compliance with NASDAQ","url":"https://stock-news.laohu8.com/highlight/detail?id=2675386074","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675386074?lang=en_us&edition=fundamental","pubTime":"2026-10-13 08:51","pubTimestamp":1791852715,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261013:nFWN45Y2O1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7508","IMM.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675386910","title":"Orthocell to Present Initial Five-Patient Case Series for Use of Nerve Repair Product in Patients Undergoing Prostatectomy; Shares Up 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2675386910","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675386910?lang=en_us&edition=fundamental","pubTime":"2026-10-13 08:30","pubTimestamp":1791851437,"startTime":"0","endTime":"0","summary":"Orthocell  will present an initial five-patient case series for the use of its Remplir nerve repair product in prostatectomy procedures in clinically complex patients as a pilot for early functional recovery data, according to a Tuesday Australian bourse filing.Remplir was placed in all five patients undergoing robotic prostatectomy, per the filing. All patients underwent extensive removal of tumor tissue with nerve preservation only feasible on one side, with 80% of the patients demonstrating \"encouraging\" urinary continence outcomes, and 75% of patients with erectile function prior to surgery showed a return of erectile function.The case series will inform a planned prospective clinical trial, which will investigate the product's potential to support an earlier return of erectile function and urinary continence following radical robotic prostatectomys with advanced prostate cancer.The biotech company's shares advanced past 4% in recent trading on Tuesday.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","OCC.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675880704","title":"ASX Growth Companies With Up To 30% Insider Ownership","url":"https://stock-news.laohu8.com/highlight/detail?id=2675880704","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675880704?lang=en_us&edition=fundamental","pubTime":"2026-10-13 03:08","pubTimestamp":1791832082,"startTime":"0","endTime":"0","summary":"As the Australian share market prepares for a potentially positive start to the week, investors remain cautious about rising bond yields and their impact on market sentiment. In this environment, growth companies with substantial insider ownership can offer unique insights into potential stability and confidence within these businesses.","market":"hk","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/9612012-choice2-card/1788955963065","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/9612012-choice2-card/1788955963065"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/commercial-services/asx-c79/chrysos-shares/news/asx-growth-companies-with-up-to-30-insider-ownership","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/commercial-services/asx-c79/chrysos-shares/news/asx-growth-companies-with-up-to-30-insider-ownership","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7506","SKS.AU","BK7023","BK7064","BK7110","BK7508","BGD.AU","LYL.AU","BK7095","BK7016","FRS.AU","TCG.AU","PDI.AU","BK7050","BK7104","AV1.AU","AEM.AU","BK7055","WZR.AU","BK7501","SPL.AU","TOR.AU","BK7096","C79.AU","AR1.AU","BK7017","BK7093"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675807010","title":"ASX Penny Stocks To Watch In October 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2675807010","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675807010?lang=en_us&edition=fundamental","pubTime":"2026-10-13 03:01","pubTimestamp":1791831712,"startTime":"0","endTime":"0","summary":"As the Australian share market prepares to open with mixed signals from futures, investor sentiment remains cautious amid concerns about rising bond yields and geopolitical tensions. Despite these uncertainties, penny stocks—often representing smaller or newer companies—continue to capture the interest of investors seeking unique opportunities. These stocks, while traditionally seen as speculative, can offer surprising value when backed by strong financials and resilience.","market":"sg","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/asx-penny-stocks-to-watch-in-october-2026-3","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/asx-penny-stocks-to-watch-in-october-2026-3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["PICK","BK7501","SBM.AU","BK7508","VTM.AU","BK7506","BK7095","BK4535","BK7067","MSB.AU","BK7104"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674389874","title":"Racura Oncology Clears RC220 Dose Escalation to 100 Mg/m2 in Phase 1 Harness-1 NSCLC Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2674389874","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674389874?lang=en_us&edition=fundamental","pubTime":"2026-10-12 19:00","pubTimestamp":1791802829,"startTime":"0","endTime":"0","summary":"Racura Oncology clears RC220 dose escalation to 100 mg/m2 in Phase 1 HARNESS-1 NSCLC trialRacura Oncology cleared to escalate RC220 dosing in the Phase 1 HARNESS-1 trial combining RC220 with AstraZene","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261012:nNDL1kM8qN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7508","RAC.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674874816","title":"Racura Oncology Cleared to Escalate Rc220 to 100 Mg/M2 in Phase 1 Harness-1 Trial in Egfr-Mutant Non-Small Cell Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2674874816","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674874816?lang=en_us&edition=fundamental","pubTime":"2026-10-12 19:00","pubTimestamp":1791802801,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261012:nTUABW9YND:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RAC.AU","BK7067","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674847847","title":"Racura Oncology Says Safety Review Committee Approved Planned Dose Escalation in Phase 1 Lung Cancer Combination Therapy Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2674847847","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674847847?lang=en_us&edition=fundamental","pubTime":"2026-10-12 09:08","pubTimestamp":1791767320,"startTime":"0","endTime":"0","summary":"Racura Oncology  said the Safety Review Committee has cleared RC220 to move to the next planned dose level of 100 milligrams per square meter in the phase one Harness-1 trial, according to a Monday filing with the Australian bourse.The trial is assessing the safety and tolerability of the company's RC220, an intravenous formulation of anti-cancer drug bisantrene in combination with osimertinib in patients with epidermal growth factor receptor-mutant non-small cell lung cancer, the filing said.The committee found no dose-limiting toxicities or treatment-related concerns in group one patients during the safety observation period, per the filing.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","RAC.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674930841","title":"Acrux - FDA Confirms Two 24-Week Phase Iii Trials Required for Efficacy in Hsdd","url":"https://stock-news.laohu8.com/highlight/detail?id=2674930841","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674930841?lang=en_us&edition=fundamental","pubTime":"2026-10-12 06:30","pubTimestamp":1791757841,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261011:nTUEBHYXCJ:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","ACR.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674419588","title":"Acrux - FDA Confirms Acrux Eligible to Apply for 3-Year Exclusivity Period","url":"https://stock-news.laohu8.com/highlight/detail?id=2674419588","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674419588?lang=en_us&edition=fundamental","pubTime":"2026-10-12 06:30","pubTimestamp":1791757841,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261011:nTUEBHYXCJ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7096","ACR.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674416728","title":"Acrux Ltd-FDA Clears Regulatory Pathway for Female Testosterone Mdts","url":"https://stock-news.laohu8.com/highlight/detail?id=2674416728","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674416728?lang=en_us&edition=fundamental","pubTime":"2026-10-12 06:30","pubTimestamp":1791757841,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261011:nTUEBHYXCJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","ACR.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674846245","title":"ASX Growth Stocks Insiders Are Betting On","url":"https://stock-news.laohu8.com/highlight/detail?id=2674846245","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674846245?lang=en_us&edition=fundamental","pubTime":"2026-10-12 03:08","pubTimestamp":1791745683,"startTime":"0","endTime":"0","summary":"As the Australian share market prepares for a potentially positive start to the week, buoyed by recent gains on Wall Street, investors remain cautious about rising bond yields and their potential impact. In this environment of mixed signals and geopolitical considerations, growth companies with high insider ownership can offer unique insights into potential opportunities, as insiders often have a deep understanding of their company's prospects.","market":"nz","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/2053000-choice2-card/1788948823050","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/2053000-choice2-card/1788948823050"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/materials/asx-smi/santana-minerals-shares/news/asx-growth-stocks-insiders-are-betting-on-1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/materials/asx-smi/santana-minerals-shares/news/asx-growth-stocks-insiders-are-betting-on-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["TOR.AU","AR1.AU","BK7016","SXE.AU","BK7501","BK7055","SMI.AU","AEM.AU","BK7096","BK7095","FRS.AU","BGD.AU","WZR.AU","BK7093","PDI.AU","BK7023","BK7110","BK7104","BK7508","BK7017","SKS.AU","SPL.AU","AV1.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674909448","title":"Top 3 Australian Founder Led Growth Stocks To Watch In October 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2674909448","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674909448?lang=en_us&edition=fundamental","pubTime":"2026-10-10 23:35","pubTimestamp":1791646554,"startTime":"0","endTime":"0","summary":"Australian investors are watching borrowing costs climb as global bond yields push higher, which puts a premium on companies that can grow under their own steam and have leaders with real skin in the game. That combination can be hard to find. This article looks at fast growing local businesses where insiders hold meaningful stakes and analyst outlooks are upbeat, and highlights 3 stocks from that group that may be worth closer attention.\nThe three stocks below are just a starting sample from...","market":"sg","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/top-3-australian-founder-led-growth-stocks-to-watch-in-octob","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/top-3-australian-founder-led-growth-stocks-to-watch-in-octob","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["XAO.AU","IIGF.AU","OZR.AU","STW.AU","TLX.AU","IOZ.AU","E200.AU","QRE.AU","USD","IMLC.AU","TLX","VAS.AU","SLF.AU","CDA.AU","XJO.AU","BK7084","USD.AU","BK7067","XKO.AU","DACE.AU","QFN.AU","BBOZ.AU","BK7501","BEAR.AU","OZF.AU","IISV.AU","VAP.AU","GIVE.AU","MSB.AU","GEAR.AU","BK4139","EIGA.AU","ZYAU.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674899595","title":"Is Building Envelope Expansion Altering The Investment Case For Carlisle Companies (CSL)?","url":"https://stock-news.laohu8.com/highlight/detail?id=2674899595","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674899595?lang=en_us&edition=fundamental","pubTime":"2026-10-10 15:33","pubTimestamp":1791617605,"startTime":"0","endTime":"0","summary":"Carlisle Companies is seeing strong demand in its Carlisle Construction Materials and Carlisle Weatherproofing Technologies units, while expanding its building envelope portfolio through acquisitions such as Bonded Logic and ThermaFoam and continuing a 50 year streak of dividend increases.\nThe decision to lift the 2026 share repurchase target and extend a multi decade record of dividend growth indicates that Carlisle Companies is placing significant emphasis on capital return alongside...","market":"hk","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/3031000-choice1-card/1788980882312","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/3031000-choice1-card/1788980882312"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/capital-goods/nyse-csl/carlisle-companies/news/is-building-envelope-expansion-altering-the-investment-case","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/capital-goods/nyse-csl/carlisle-companies/news/is-building-envelope-expansion-altering-the-investment-case","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU1169589451.USD","SG9999004303.SGD","BK7501","LU0728928796.USD","BK7067","CSL.AU","BK7511","BK7508","LU1169590202.USD","BK4086","CSL","SGXZ23171101.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674690428","title":"Why PolyNovo Fell Even As Sales Rose","url":"https://stock-news.laohu8.com/highlight/detail?id=2674690428","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674690428?lang=en_us&edition=fundamental","pubTime":"2026-10-10 02:22","pubTimestamp":1791570148,"startTime":"0","endTime":"0","summary":"If you had seen the sharp disagreement over PolyNovo in mid 2025 and decided to sit it out, the result might look different today. Holding PolyNovo over the past year would have meant a 37.0% loss, including dividends. Fresh numbers now show higher revenue but a thinner net margin in H2 2026 compared with H2 2025. If you rewind to October 2025, what assumptions on pricing power and costs were already on record that might have signalled this profit squeeze?\nThe useful thing about a Narrative...","market":"sg","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6022000-choice1-card/1788992506868","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6022000-choice1-card/1788992506868"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/healthcare/asx-pnv/polynovo-shares/news/why-polynovo-fell-even-as-sales-rose","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/healthcare/asx-pnv/polynovo-shares/news/why-polynovo-fell-even-as-sales-rose","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7126","PNV.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674831709","title":"Thailand's Forex Reserves Fall to $276.1 Billion in September","url":"https://stock-news.laohu8.com/highlight/detail?id=2674831709","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674831709?lang=en_us&edition=fundamental","pubTime":"2026-10-09 15:52","pubTimestamp":1791532366,"startTime":"0","endTime":"0","summary":"Thailand's gross international reserves fell to $276.1 billion in September, according to data the Bank of Thailand  released on Friday.The reading compares with the $283.1 billion recorded the previous month.The monthly movement was primarily driven by a decline in foreign currency reserves, which reached $237.9 billion, while the central bank's gold holdings were valued at $31.4 billion.Meanwhile, the country's net forward position stood at $24.3 billion.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7502","BOT","BK7508","BK7096","BOT.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674688773","title":"Australia's CSL Rises After Jefferies Sees Plasma Yield Upside","url":"https://stock-news.laohu8.com/highlight/detail?id=2674688773","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674688773?lang=en_us&edition=fundamental","pubTime":"2026-10-09 11:31","pubTimestamp":1791516691,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's CSL rises after Jefferies sees plasma yield upside** Shares of Australia's CSLCSL.AXrise as much as 1.62% to A$184.4** Jefferies says the biotechnology giant remains rated \"hold\", after its US plasma platform shift may lift efficiency but risks collection disruption** Brokerage says CSL will replace Terumo systems with Haemonetics equipment across about 330 US centres by the end of 2027** Jefferies notes channel checks suggest the new platform can deliver up to a 15% improvement in plasma collection yield** Adds a single newer platform is aligned with CSL's cost-per-litre and gross margin goals, though benefits are likely to emerge gradually** Jefferies says \"the key risks are collection disruption during the changeover\" and is watching for any disclosure of costs, savings and impairment** Stock for the week up 5.1% and putting the stock on track for its best week in a month","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261009:nL6N45V057:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HAE","LU1169590202.USD","IE00B64QTZ34.USD","BK7501","BK7067","CSL.AU","LU0012050646.USD","IE00BLDYK493.USD","LU0205194284.USD","BK4198","LU1169589451.USD","LU0106261612.USD","BK7508","LU0205193047.USD","IE0034390439.USD","BK7511","IE00B19Z6F94.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674827878","title":"Terumo, CSL Plasma Mutually Terminate Supply Agreement; Terumo Expects $610 Million Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2674827878","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674827878?lang=en_us&edition=fundamental","pubTime":"2026-10-09 10:46","pubTimestamp":1791513965,"startTime":"0","endTime":"0","summary":"Terumo  has mutually agreed with CSL Plasma to end their supply agreement for source plasma collection devices, and expects a loss of $610 million, according to a Thursday Tokyo bourse filing.The loss comprises $450 million in non-cash impairment losses and $160 million in transition, termination, and restructuring costs.Subsequently, Terumo revised its full-year guidance for the fiscal year ending March 31, 2027, cutting profit attributable to owners of the parent to 120 billion yen from 193.1 billion yen initially.Basic earnings per share estimates dropped to 81.35 yen from 130.91 yen, while revenue targets were cut to 1.23 trillion yen from 1.239 trillion yen.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7511","BK7067","BK7501","YCL","BK7508","CSL.AU","HEWJ","FXY","YCS"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":1,"totalSize":110,"code":"91000000","status":"200"}]}}